Segawa M
Segawa Neurological Clinic for Children, 2-8 Surugadai Kanda, Chiyoda-ku, 101-0062, Tokyo, Japan.
Brain Dev. 2000 Sep;22 Suppl 1:S65-80. doi: 10.1016/s0387-7604(00)00148-0.
Hereditary progressive dystonia with marked diurnal fluctuation or the strictly defined dopa-responsive dystonia (HPD/DRD) is an autosomally dominantly inherited dystonia caused by abnormalities of the gene of the GTP cyclohydrolase I (GCH 1) located on the 14q22. 1-q22.2. The heterozygotic gene abnormality induces partial decrement of tetrahydrobiopterin (BH4) and affects synthesis of tyrosine hydroxylase (TH) rather selectively. The reduction of TH exists at the terminals of the nigrostriatal (NS) dopamine (DA) neuron, predominantly in the ventral area of the striatum and disfacilitates the D1 receptor-striatal direct pathway. This consequently disinhibit the inhibitory efferent pathways and develops postural dystonia via the particular descending pathways to the reticulospinal tract and postural tremor via the ascending pathways to the ventralis lateralis (VL) nucleus of the thalamus. This also inhibits the efferents to the superior colliculus, and affects voluntary saccade but spares that to the pedunculo-pontine nucleus (PPN) preserving locomotive movement clinically. The DA-D2 receptors, the striatal indirect pathways or the efferent connecting to these pathways are not involved in the pathophysiology of HPD/DRD. So parkinsonian plastic rigidity, parkinsonian resting tremor, cogwheel rigidity or levodopa induced dyskinesia are not observed. In some patients, particularly in compound hetereozygotes, there are symptoms suggesting the involvement of serotonergic neurons or those thought to be caused by exaggeration of DA-D2 receptors. Neuropathologically there is no degenerative changes. Clinical laboratory examinations suggest that levels of TH and DA activities are around 20% of the normal values throughout the course of illness. Therefore, the age-dependent clinical course, marked progression in the first one and one half decades, its subsiding in the third decade and almost stationary course from the fourth decade are just the reflection of age-related decremental variation of the TH activities at the terminal of the normal NS-DA neuron. The diurnal fluctuation is also the reflection of circadian oscillation of the TH activities at the terminal. Functional maturation of the striatal indirect pathways in the first one and one half decades and developmental decremental variation of the DA-D2 receptor in the first three decades also reflect in the age-dependent variation of symptoms by modulating the background tone of muscle. The later functional development of the ascending efferents of the basal ganglia to the thalamus, may cause the postural tremor which appears in the second decade and becomes predominant in the fourth decade. Early decrease of TH due to deficiency of BH4 in HPD/DRD also affects the DA-D4 receptor of the tuberoinfundibular DA neuron and cause stagnation of increase of body length in childhood. With normal preservation of the fundamental function of the NS-DA neuron, levodopa, by replacing the DA content at the terminal, alleviates the motor symptoms completely and the effects sustain without any side effects. Levodopa also improves the short body length, if it is administrated before puberty. Up to now 60 mutations have been detected in the GCH 1 gene. The locus of mutation differs among families except for two pare of families with different ethnic background which showed identical mutations. Experimentally, one abnormal heterozygotic gene decreased the production of the enzyme to less than 50%, e.g. some below 20% and others around 30-40%, which clinically as symptomatic patients and asymptomatic carriers, respectively. Other experiments show dominant negative effects which differ among families or the loci of mutation. These might be the background for developing the intra-familial variation, that is, in some there is anticipation, and in the other the symptoms and clinical course are identical or vary in a family without any relation to the generation. (ABSTRACT TRUNCATED)
遗传性进行性肌张力障碍伴明显昼夜波动或严格定义的多巴反应性肌张力障碍(HPD/DRD)是一种常染色体显性遗传的肌张力障碍,由位于14q22.1 - q22.2的GTP环化水解酶I(GCH 1)基因异常引起。杂合子基因异常导致四氢生物蝶呤(BH4)部分减少,并选择性地影响酪氨酸羟化酶(TH)的合成。TH的减少存在于黑质纹状体(NS)多巴胺(DA)神经元的终末,主要在纹状体腹侧区域,使D1受体 - 纹状体直接通路功能减弱。这进而解除对抑制性传出通路的抑制,通过特定的下行通路至网状脊髓束发展为姿势性肌张力障碍,通过上行通路至丘脑腹外侧(VL)核发展为姿势性震颤。这也抑制了向上丘的传出,影响随意性扫视,但不影响至脚桥核(PPN)的传出,临床上保留了运动功能。DA - D2受体、纹状体间接通路或与这些通路相连的传出不参与HPD/DRD的病理生理过程。因此,不会观察到帕金森病样的铅管样强直、帕金森病静止性震颤、齿轮样强直或左旋多巴诱发的运动障碍。在一些患者中,特别是复合杂合子,存在提示血清素能神经元受累或被认为由DA - D2受体过度激活引起的症状。神经病理学上无退行性改变。临床实验室检查表明,在疾病全过程中,TH和DA活性水平约为正常值的20%。因此,年龄依赖性的临床病程,在最初的十五年中明显进展,在第三个十年中缓解,从第四个十年开始几乎静止,正是正常NS - DA神经元终末TH活性随年龄递减变化的反映。昼夜波动也是终末TH活性昼夜振荡的反映。纹状体间接通路在最初的十五年中的功能成熟以及DA - D2受体在最初三十年中的发育性递减变化,也通过调节肌肉的背景张力反映在症状的年龄依赖性变化中。基底神经节至丘脑的上行传出的后期功能发育,可能导致在第二个十年出现并在第四个十年占主导的姿势性震颤。HPD/DRD中由于BH4缺乏导致的TH早期减少,也影响结节漏斗DA神经元的DA - D4受体,并导致儿童期身长增长停滞。在NS - DA神经元基本功能正常保留的情况下,左旋多巴通过替代终末的DA含量,完全缓解运动症状,且效果持续且无任何副作用。如果在青春期前给药,左旋多巴还可改善身长。到目前为止,已在GCH 1基因中检测到60种突变。除了两组具有不同种族背景但显示相同突变的家系外,不同家系的突变位点不同。实验中,一个异常杂合子基因使酶的产生减少至低于50%,例如一些低于20%,另一些约为30 - 40%,临床上分别表现为有症状患者和无症状携带者。其他实验显示显性负效应在不同家系或突变位点之间存在差异。这些可能是导致家系内变异的背景,即,在一些家系中有遗传早现现象,而在另一些家系中,症状和临床病程相同或在一个家系中变化且与代际无关。(摘要截选)